PBAC's latest decision on Empagliflozin, empagliflozin with metformin, linagliptin, linagliptin with metformin: Recommended with restriction (2017). Considered for Type 2 Diabetes Mellitus in patients uncontrolled on dual oral therapy, for use in triple oral therapy (DPP4 inhibitor + SGLT2 inhibitor + metformin).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with type 2 Diabetes Mellitus who are uncontrolled on dual oral therapy and require triple oral therapy with a DPP4 inhibitor, SGLT2 inhibitor, and metformin.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
Other
Economic model
Not modelled
ICER note
This is a minor submission relying on evidence from a concurrent major submission (empagliflozin with linagliptin FDC). No separate economic analysis performed; cost-effectiveness established via reference to the concurrent major submission.